Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart

The Journal of Pharmacology and Experimental Therapeutics
E SalvatorelliG Minotti

Abstract

Secondary alcohol metabolites and reactive oxygen species mediate cardiomyopathy induced by cumulative doses of antitumor anthracyclines, such as doxorubicin and epirubicin. Epirubicin exhibits a defective conversion to both toxic species, thereby inducing cardiotoxicity at doses higher than equiactive to doxorubicin; however, the gain in cardiac tolerability seems to be marginal compared with the magnitude of the metabolic defects of epirubicin. Cardiomyopathy may occur independent of toxic metabolites if a given anthracycline tends to accumulate in the heart; therefore, we characterized whether epirubicin showed an unusual accumulation in human myocardial strips incubated in plasma. Epirubicin exhibited a higher uptake and reached myocardial levels 2 times higher than those of doxorubicin. Epirubicin also showed a unique metabolization to doxorubicinolone, the product of epirubicin deglycosidation and carbonyl reduction. In diffusing from the strips to plasma, doxorubicinolone caused membrane permeation effects that augmented epirubicin elimination. Experiments with purified doxorubicinolone showed that the efflux of 1 mol doxorubicinolone promoted the concomitant elimination of as many as approximately 40 mol epirubicin. Dox...Continue Reading

References

May 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R D OlsonR J Boucek
Nov 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·E J BowmanK Altendorf
Mar 1, 1988·Biochemical Pharmacology·P M Sokolove, R G Shinaberry
May 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L GianniG Bonadonna
Jan 1, 1997·Free Radical Biology & Medicine·L Gille, H Nohl
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A GennariP F Conte
Oct 19, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O PaganiA Goldhirsch
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G GrasselliL Gianni
Apr 20, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M UntchH J Lück
Apr 22, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Julianne L HolleranSu-Shu Pan
Aug 2, 2006·Journal of Molecular and Cellular Cardiology·Malgorzata Tokarska-SchlattnerUwe Schlattner
Dec 1, 2006·The Journal of Pharmacology and Experimental Therapeutics·Emanuela SalvatorelliGiorgio Minotti
May 1, 2007·The Journal of Pharmacology and Experimental Therapeutics·Pierantonio MennaGiorgio Minotti
Jul 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M SuterMartine J Piccart-Gebhart
Nov 27, 2007·International Journal of Biological Macromolecules·Feng-Ling CuiJuan Du
Feb 16, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Onkar S BainsK Wayne Riggs
Apr 2, 2008·Chemical Research in Toxicology·Pierantonio MennaGiorgio Minotti
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca GianniDouglas B Sawyer

❮ Previous
Next ❯

Citations

Oct 30, 2009·Archivum Immunologiae Et Therapiae Experimentalis·Yi-Wei ZhangLei Wei
Dec 3, 2014·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jan Czepas, Krzysztof Gwoździński
Jun 4, 2011·Expert Opinion on Drug Safety·Pierantonio MennaGiorgio Minotti
Aug 30, 2011·Expert Opinion on Drug Metabolism & Toxicology·Michael Weiss
Sep 18, 2012·European Journal of Medicinal Chemistry·Davide PirolliMaria Cristina De Rosa
Oct 31, 2009·Pharmacology & Therapeutics·Emanuel RaschiFabrizio De Ponti
May 6, 2015·Pediatric Cardiology·Elżbieta Sadurska
May 28, 2016·Heart Failure Reviews·Donato MeleGiuseppe Mercuro
May 7, 2013·Journal of Cardiovascular Pharmacology·Brock T JensenReid Hayward
Mar 26, 2010·The Journal of Pharmacology and Experimental Therapeutics·Giorgio MinottiPierantonio Menna
May 18, 2016·Journal of Cardiovascular Medicine·Donato MelePaolo Spallarossa
Feb 5, 2013·Expert Review of Hematology·Dionysios Papadatos-Pastos, Ruth Pettengell
Oct 19, 2016·Journal of Cardiovascular Medicine·Donato MelePaolo Spallarossa
Dec 4, 2009·Chemical Research in Toxicology·Pierantonio MennaGiorgio Minotti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.